Treating CTCL by targeting the PI3K/AKT/mTOR pathway has been proven effective alone (64–67) or in combination with other strategies (45, 68), whereas the treatment responses vary among individuals. Here, AKT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.